Chia Tai Enterprises International Limited (3839.HK)
HKD 1.68
(0.0%)
HKD 1.68
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.28 Million USD | 113.24% |
| 2022 | 5.17 Million USD | -74.69% |
| 2021 | 20.86 Million USD | -12.08% |
| 2020 | 23.72 Million USD | -3.35% |
| 2019 | 24.54 Million USD | -18.03% |
| 2018 | 29.95 Million USD | 20.69% |
| 2017 | 24.81 Million USD | 25.78% |
| 2016 | 19.72 Million USD | -7.67% |
| 2015 | 21.36 Million USD | -37.93% |
| 2014 | 34.42 Million USD | 49.82% |
| 2013 | 22.97 Million USD | -13.96% |
| 2012 | 26.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.4 Million USD | 262.41% |
| 2024 Q2 | 2.34 Million USD | 67.61% |
| 2023 Q2 | 73 Thousand USD | -97.28% |
| 2023 Q4 | 496 Thousand USD | -49.64% |
| 2023 FY | - USD | 113.24% |
| 2023 Q3 | 985 Thousand USD | 1249.32% |
| 2023 Q1 | 2.67 Million USD | 116.09% |
| 2022 FY | - USD | -74.69% |
| 2022 Q3 | -537 Thousand USD | -117.99% |
| 2022 Q4 | 1.24 Million USD | 330.91% |
| 2022 Q1 | 2.36 Million USD | -39.32% |
| 2022 Q2 | 2.98 Million USD | 26.39% |
| 2021 Q1 | 2.13 Million USD | 53.76% |
| 2021 FY | - USD | -12.08% |
| 2021 Q4 | 3.89 Million USD | 81.88% |
| 2021 Q3 | 2.13 Million USD | -20.18% |
| 2021 Q2 | 2.68 Million USD | 25.46% |
| 2020 Q2 | 1.45 Million USD | -14.37% |
| 2020 Q4 | 1.38 Million USD | 9.07% |
| 2020 Q3 | 1.27 Million USD | -12.17% |
| 2020 FY | - USD | -3.35% |
| 2020 Q1 | 1.69 Million USD | 18.13% |
| 2019 Q2 | 2.6 Million USD | -9.23% |
| 2019 Q1 | 2.86 Million USD | -16.33% |
| 2019 FY | - USD | -18.03% |
| 2019 Q4 | 1.43 Million USD | -1.24% |
| 2019 Q3 | 1.45 Million USD | -44.16% |
| 2018 Q4 | 3.42 Million USD | 184.62% |
| 2018 Q2 | 594 Thousand USD | -78.74% |
| 2018 Q1 | 2.79 Million USD | 34.98% |
| 2018 FY | - USD | 20.69% |
| 2018 Q3 | 1.2 Million USD | 102.53% |
| 2017 Q4 | 2.06 Million USD | 48.6% |
| 2017 Q2 | 466 Thousand USD | -76.32% |
| 2017 Q1 | 1.96 Million USD | -46.27% |
| 2017 FY | - USD | 25.78% |
| 2017 Q3 | 1.39 Million USD | 198.93% |
| 2016 Q3 | 2.21 Million USD | -40.05% |
| 2016 Q2 | 3.7 Million USD | 37.82% |
| 2016 Q1 | 2.68 Million USD | -5.37% |
| 2016 Q4 | 3.66 Million USD | 65.04% |
| 2016 FY | - USD | -7.67% |
| 2015 FY | - USD | -37.93% |
| 2015 Q4 | 2.83 Million USD | -25.99% |
| 2015 Q3 | 3.83 Million USD | -4.59% |
| 2015 Q2 | 4.02 Million USD | -11.08% |
| 2015 Q1 | 4.52 Million USD | -46.01% |
| 2014 Q4 | 8.37 Million USD | 115.94% |
| 2014 Q3 | 3.87 Million USD | 21.62% |
| 2014 Q2 | 3.18 Million USD | 0.0% |
| 2014 Q1 | 3.18 Million USD | 0.0% |
| 2014 FY | - USD | 49.82% |
| 2013 FY | - USD | -13.96% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 92.495% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 99.619% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 108.715% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 90.081% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 122.473% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 89.721% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 97.302% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 85.27% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 143.135% |
| SSY Group Limited | 2.11 Billion HKD | 99.466% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 94.477% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 97.374% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.927% |